The Observational Medical Outcomes Partnership (OMOP) is a public-private partnership designed to help improve the monitoring of drugs for safety. The partnership will conduct a two-year initiative to research methods that are feasible and useful to analyze existing healthcare databases to identify and evaluate safety and benefit issues of drugs already on the market. OMOP draws on the expertise and resources of the pharmaceutical industry, academic institutions, non-profit organizations, the Food and Drug Administration (FDA), and other federal agencies. It is funded and managed through the Foundation for the National Institutes of Health.

Founded in 1974 by Bernard Jambon, Groupe MAPI has offices in the U.K., U.S., Netherlands, Singapore and France. Mapi operates on the principle that in today's world, to perform well in its market, a drug needs to be thoroughly documented and judged by its various properties and qualities. Areas of expertise include clinical trials (phases II through IV), pharmaco-epidemiology and pharmaco-economic studies, and all aspects of patient reported outcomes studies worldwide. Groupe MAPI is headquartered in Lyon, France.

Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas of cardiology, dermatology, immunology, infectious disease and urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients, and partners.

Enzon is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden our revenue base or provide access to promising new technologies or product development opportunities.

Genzyme is one of the world's foremost biotechnology companies and is dedicated to making a major positive impact on the lives of people with serious diseases. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant and immune disease, cancer, and diagnostic testing.

Headquartered in the UK and with operations based in the US, GlaxoSmithKline is one of the industry leaders, with an estimated seven percent of the world's pharmaceutical market. GSK produces medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, GSK is a leader in the important area of vaccines and is developing new treatments for cancer.

Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, Roche has been active in the discovery, development, manufacturing, and marketing of novel healthcare solutions. Roche's products and services address prevention, diagnosis, and treatment of diseases, thus enhancing well-being and quality of life.

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The company believes that maintaining a full pipeline of drug candidates with the potential to become first- or best-in-class therapies for large and growing markets is critical to its long-term growth and success. Idenix seeks to optimize the value of new drug candidates through efficient, rapid and market-driven clinical development programs. Today, Idenix has a robust pipeline focused on agents that it believes will advance the treatment of hepatitis C and HIV.

Manhattan-based Indigo Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development of new treatments for cardiovascular diseases, currently concentrating on peripheral arterial disease (PAD).

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. The Company's products include therapies for inflammation, ocular pain, glaucoma, allergy, dry eye, and vitreous hemorrhage. ISTA currently markets three products, which include a product for the treatment of inflammation and pain following cataract surgery, a product for the treatment of glaucoma, and a product for use as a spreading agent.

Kaiser Permanente is the largest nonprofit health plan in the United States, serving 8.6 million members in nine states and the District of Columbia. Kaiser Permanente is an integrated health delivery system, providing and coordinating the entire scope of care for our members, including preventative care, well-baby and prenatal care, immunizations, emergency care, screening diagnostics, hospital and medical services, and pharmacy services.

Maxim Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic products with the potential to improve survival and maintain the quality of life of patients suffering from cancers and chronic liver diseases. Maxim has attracted a talented group of experienced managers and a team of employees dedicated to commercializing life-enhancing product candidates.

Novartis is a global pharmaceutical leader, which discovers, devleops, and markets innovative products to cure diseases. Novartis offers a wide range of healthcare products through its Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health divisions. Novartis' therapeutic areas cover a wide range of disciplines, including arthritis and bone metabolism, cardiovascular and metabolic diseases, dermatology / immunopathology, infectious disease, nervous system disorders, oncology, ophthalmics, transplantation, and respiratory diseases. Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz. Headquarted in Basel, Novartis operates in 140 countries.

Oncovance provides information management and analytical services coupled with innovative, proprietary predictive solutions to the healthcare industry. The Company has developed a suite of technologies and products that streamline therapeutics development, support and promote diagnostic and therapeutic products, and improve the quality of patient care. Initial efforts are directed toward urologic cancer and benign prostate hyperplasia.

Having pioneered the field, Organogenesis is the leading regenerative medicine company. A new era in medicine arrived when Organogenesis received the first FDA approval for a living, human cell-based therapy. This product is now the leading regenerative medicine brand in the world. This was the culmination of two decades of innovative research by a dedicated team of scientists.

Pacira is a pharmaceutical company with a primary focus on formulating, developing and manufacturing controlled-release injectable products. Based in San Diego, California, Pacira has access to some of the nation's most prestigious teaching institutions and a readily available work-force of highly trained scientific, biomedical and engineering professionals. At its two La Jolla facilities, all major functions of the company are housed, including formulation research, product development, FDA and GMP compliant manufacturing and testing, and all administrative/executive departments.

The Pharmaceutical Research and Manufacturers of American (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA conducts effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical / biotechnology research companies.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs.

Three Rivers Pharmaceuticals^® is a specialty drug manufacturer dedicated to helping patients by offering them specialized therapies. They develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. With extensive knowledge and experience, Three Rivers Pharmaceuticals focuses on specialized therapies, while delivering elite, world-class customer service.

Wyeth is a global leader in prescription pharmaceuticals, non-prescription consumer health care products, and pharmaceuticals for animal health. Wyeth's products include pharmaceuticals, consumer health care products, and animal health care products, with leading products in the areas of women's health care, neuroscience, musculoskeletal disorders, cardiovascular therapy, vaccines and infectious disease, hemophilia, immunology, and oncology. Wyeth's products are sold in more than 145 countries, and its product portfolio includes innovative treatments across a wide range of therapeutic areas. With this depth of resources, Wyeth will continue to lead the way in the development of novel therapies that address critical global health needs.

Founded in 1915, Geisinger is a physician-led health care system, dedicated to health care, education, research, and service spanning 40 counties of 20,000 square miles and serving 2.5 million people. The system is committed to educating the next generation of caregivers - physicians, nurses, technologists, pharmacists - and to providing lifelong learning. Geisinger's collaborations with local hospitals, referring physicians, communities, and our patients mean service to the entire region, with benefits that extend beyond our system - models of care that can be replicated nationwide, particularly in rural areas.

NCGR is a private, nonprofit life sciences research institute whose mission is to translate research at intersections between bioscience, computing and mathematics into improvements in infectious disease, global health, and nutrition. The company's objectives include improved diagnosis, control and cure of infectious disease, and better nutrition and food safety.

The Department of Defense (DoD) SBIR and STTR programs fund a billion dollars each year in early-stage R&D projects at small technology companies -- projects that serve a DoD need and have commercial applications. The SBIR Program provides up to $850,000 in early-stage R&D funding directly to small technology companies (or individual entrepreneurs who form a company).

LSGPA partners with a range of institutions, including local research universities, colleges, medical centers, economic development agencies and companies both small and large, to identify needs and opportunities. LSGPA then works to help transfer technologies, to develop new companies, to provide support for existing companies (particularly those seeking to expand or relocate), and to ensure that the infrastructure necessary to support a thriving life sciences industry keeps pace with development.

The physicians and researchers of the Penn State Hershey Medical Center receive international acclaim for their accomplishments in patient care, education, and research. ProSanos has collaborated with Medical Center faculty on the study of pathway modeling of neurological diseases.

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. For NIAID, ProSanos produced software that allows researchers to analyze data from disparate sources, providing an important tool for improvements in diagnosis and treatment of kidney disease. The project was conducted in collaboration with the University of Iowa.

The Napa Group is a professional consulting organization that focuses on leadership effectiveness and organizational performance. Its clients range from entrepreneurial businesses to major educational institutions. For ProSanos, the Napa Group assists in strategic positioning of the company and in leveraging leadership and organizational capacities to execute sound business initiatives and outcomes.

ProSanos leverages Microsoft technologies in many of its products. From the development platform to the server infrastructure, technologies such as Microsoft.NET and Microsoft SQL Server 2005 enable ProSanos to deliver hosted software solutions.